DNJ, alpha-glucosidase inhibition, and post-meal glucose: what research shows about White Mulberry Leaf and its role in GlycoCare.
By Dr. Nathan Riley, MD · Published April 12, 2026 · Updated April 24, 2026
White Mulberry (Morus alba) has a long and practical history in East Asian traditional medicine. Its leaves have been used in traditional Japanese and Korean herbal teas for centuries, often in combination with other botanicals, as part of a daily approach to what we would now call metabolic support. In the past two decades, one specific compound isolated from mulberry leaves has attracted significant pharmacological interest: 1-deoxynojirimycin, or DNJ.
DNJ is what is known as an alpha-glucosidase inhibitor — the same mechanism of action as the prescription diabetes drug acarbose. This article unpacks the research on White Mulberry and DNJ, explains what the mechanism actually does in digestion, reviews the clinical trials, and examines how mulberry fits into a multi-ingredient formula like GlycoCare.
When you eat a carbohydrate-containing meal, the starches and sugars it contains must be broken down into simple glucose before they can be absorbed through the wall of the small intestine. This breakdown is performed by a family of digestive enzymes called alpha-glucosidases, which sit on the brush border of the intestinal lining.
If you partially inhibit these enzymes, carbohydrate digestion slows down. Glucose enters the bloodstream more gradually, and the post-meal glucose peak — the spike that follows a carbohydrate-containing meal — is blunted. This is exactly how the prescription drug acarbose works. DNJ from White Mulberry operates through the same mechanism at a more modest potency.
The practical consequence of this mechanism is specific: alpha-glucosidase inhibition affects post-meal glucose, not fasting glucose. If your fasting blood sugar is elevated, DNJ alone would not address that. If your fasting blood sugar is in a healthy range but you experience large post-meal glucose swings after carbohydrate-heavy meals, DNJ-containing botanicals are mechanistically relevant.
Clinical trials on White Mulberry leaf extract in humans have produced generally positive but modest results for post-meal glucose control. Trials have typically used a standardised extract (often standardised to DNJ content) administered shortly before a carbohydrate-containing meal, with blood glucose measured at intervals afterwards.
Representative findings include: reductions in peak post-meal glucose of roughly 10-25 percent compared to placebo; smaller area-under-the-curve for post-meal glucose, indicating less cumulative glucose exposure; and, in some trials, reductions in the insulin response required to handle the meal. Effects have been seen in both healthy adults and adults with impaired glucose tolerance.
The NIH Office of Dietary Supplements maintains fact sheets on many botanical ingredients, and primary research is indexed on PubMed under searches for "mulberry DNJ alpha-glucosidase."
Clinical trials have used White Mulberry extract doses ranging from 250 mg to 1000 mg, standardised to varying DNJ percentages. The DNJ content is what actually matters pharmacologically, not the raw extract weight. Products standardised to 1 percent DNJ or higher have been used in most trials.
Timing matters more for White Mulberry than for many other blood sugar ingredients. Because the mechanism is enzyme inhibition in the gut, the extract needs to be present in the digestive tract at the same time as the carbohydrate-containing meal. For maximum effect, the capsule should be taken shortly before or with meals, not an hour before or two hours after.
For a once-daily multi-ingredient formula like GlycoCare, this timing consideration is relevant: the formula will produce greatest effect when taken with the largest carbohydrate-containing meal of the day.
The most common side effect of alpha-glucosidase inhibition is mild digestive discomfort. Because some carbohydrate digestion is delayed, more starch reaches the lower intestine where it is fermented by gut bacteria. The result can be mild bloating, gas, or loose stools, particularly in the first week or two of use and particularly after carbohydrate-heavy meals.
This effect is dose-dependent and usually mild. It tends to diminish with continued use as the gut microbiome adapts. It is not a sign of product failure or harm — it is actually a predictable consequence of the mechanism working. That said, adults with inflammatory bowel disease, irritable bowel syndrome, or chronic digestive sensitivity should discuss White Mulberry with their clinician before starting.
As with other blood sugar-lowering ingredients, concurrent use with insulin or sulfonylureas can additively reduce glucose. The effect here is specifically on post-meal glucose, but the interaction still warrants monitoring and possible medication adjustment under clinical guidance.
White Mulberry Leaf is one of five botanicals in what we have described as the botanical glucose utilisation pathway of the GlycoCare formula. Among those five, mulberry is the one with the cleanest, most mechanism-specific relationship to post-meal glucose control through alpha-glucosidase inhibition.
The caveat, as with every ingredient in a twelve-ingredient formula, is dose. The per-capsule White Mulberry content in GlycoCare is smaller than a dedicated single-ingredient mulberry extract would deliver, and the effect on any given meal will therefore be proportionally smaller. For adults with normal glucose tolerance using GlycoCare for daily maintenance, this is reasonable. For adults specifically trying to blunt sharp post-meal glucose spikes after particularly carbohydrate-heavy meals, a higher-dose, DNJ-standardised mulberry supplement taken with those specific meals would deliver more targeted effect.
White Mulberry Leaf is mechanistically one of the most interesting ingredients in the blood sugar support category. Its active compound DNJ is a genuine alpha-glucosidase inhibitor, operating through the same pathway as a prescription diabetes drug but at gentler potency. Clinical research supports modest but real effects on post-meal glucose. The main practical considerations are taking the supplement with meals, starting with a lower dose to allow digestive adaptation, and coordinating with the prescribing clinician if blood sugar medications are in use. Within GlycoCare, White Mulberry contributes specifically to the post-meal glucose control dimension of the multi-pathway formula.
This article is for educational purposes only and is not medical advice. Always consult your physician before starting any supplement, particularly if you have diabetes, prediabetes, hypoglycemia, or take any prescription medication for blood sugar control. Individual response varies. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.